107 related articles for article (PubMed ID: 33026161)
1. Targeted Degradation of Transcription Coactivator SRC-1 through the N-Degron Pathway.
Lee Y; Heo J; Jeong H; Hong KT; Kwon DH; Shin MH; Oh M; Sable GA; Ahn GO; Lee JS; Song HK; Lim HS
Angew Chem Int Ed Engl; 2020 Sep; 59(40):17548-17555. PubMed ID: 33026161
[TBL] [Abstract][Full Text] [Related]
2. Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1.
Choi SR; Wang HM; Shin MH; Lim HS
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203850
[TBL] [Abstract][Full Text] [Related]
3. Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.
Yan F; Yu Y; Chow DC; Palzkill T; Madoux F; Hodder P; Chase P; Griffin PR; O'Malley BW; Lonard DM
PLoS One; 2014; 9(4):e95243. PubMed ID: 24743578
[TBL] [Abstract][Full Text] [Related]
4. Insights into the recognition mechanism in the UBR box of UBR4 for its specific substrates.
Jeong DE; Lee HS; Ku B; Kim CH; Kim SJ; Shin HC
Commun Biol; 2023 Nov; 6(1):1214. PubMed ID: 38030679
[TBL] [Abstract][Full Text] [Related]
5. Selective and Potent PROTAC Degraders of c-Src Kinase.
Mao W; Vandecan NM; Bingham CR; Tsang PK; Ulintz P; Sexton R; Bochar DA; Merajver SD; Soellner MB
ACS Chem Biol; 2024 Jan; 19(1):110-116. PubMed ID: 38113191
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications.
Goracci L; Desantis J; Valeri A; Castellani B; Eleuteri M; Cruciani G
J Med Chem; 2020 Oct; 63(20):11615-11638. PubMed ID: 33026811
[TBL] [Abstract][Full Text] [Related]
7. First small-molecule PROTACs for G protein-coupled receptors: inducing
Li Z; Lin Y; Song H; Qin X; Yu Z; Zhang Z; Dong G; Li X; Shi X; Du L; Zhao W; Li M
Acta Pharm Sin B; 2020 Sep; 10(9):1669-1679. PubMed ID: 33088687
[TBL] [Abstract][Full Text] [Related]
8. RNA-PROTACs: Degraders of RNA-Binding Proteins.
Ghidini A; Cléry A; Halloy F; Allain FHT; Hall J
Angew Chem Int Ed Engl; 2021 Feb; 60(6):3163-3169. PubMed ID: 33108679
[TBL] [Abstract][Full Text] [Related]
9. PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases.
Jiang X; Zhou J; Wang Y; Liu X; Xu K; Xu J; Feng F; Sun H
Eur J Med Chem; 2021 Jan; 210():112949. PubMed ID: 33097303
[TBL] [Abstract][Full Text] [Related]
10. Charting a New Path Towards Degrading Every Protein.
Nabet B
Chembiochem; 2021 Feb; 22(3):483-484. PubMed ID: 33103843
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs.
Gao H; Wu Y; Sun Y; Yang Y; Zhou G; Rao Y
ACS Med Chem Lett; 2020 Oct; 11(10):1855-1862. PubMed ID: 33062164
[TBL] [Abstract][Full Text] [Related]
12. Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay.
Lin W; Li Y; Min J; Liu J; Yang L; Lee RE; Chen T
Bioconjug Chem; 2020 Nov; 31(11):2564-2575. PubMed ID: 33070611
[TBL] [Abstract][Full Text] [Related]
13. SMARCA2/4 PROTAC for Targeted Protein Degradation and Cancer Therapy.
Kargbo RB
ACS Med Chem Lett; 2020 Oct; 11(10):1797-1798. PubMed ID: 33062156
[No Abstract] [Full Text] [Related]
14. Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer.
Cimas FJ; Niza E; Juan A; Noblejas-López MDM; Bravo I; Lara-Sanchez A; Alonso-Moreno C; Ocaña A
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33086530
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of PROTACs.
Benowitz AB; Jones KL; Harling JD
Expert Opin Ther Pat; 2021 Jan; 31(1):1-24. PubMed ID: 33081540
[TBL] [Abstract][Full Text] [Related]
16. PROTAC Compatibilities, Degrading Cell-Surface Receptors, and the Sticky Problem of Finding a Molecular Glue.
Tian C; Burgess K
ChemMedChem; 2021 Jan; 16(2):316-318. PubMed ID: 33112038
[TBL] [Abstract][Full Text] [Related]
17. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
18. Photopharmacology-based small-molecule proteolysis targeting chimeras: optical control of protein degradation.
Li W; Elhassan RM; Fang H; Hou X
Future Med Chem; 2020 Nov; 12(22):1991-1993. PubMed ID: 33054433
[No Abstract] [Full Text] [Related]
19. A kinetic proofreading model for bispecific protein degraders.
Bartlett DW; Gilbert AM
J Pharmacokinet Pharmacodyn; 2021 Feb; 48(1):149-163. PubMed ID: 33090299
[TBL] [Abstract][Full Text] [Related]
20. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
